PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028424
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028424
Infectious Disease Point-of-care Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of infectious disease point-of-care (POC) diagnostics Market
The global infectious disease point-of-care (POC) diagnostics market is undergoing a notable transition due to shifting healthcare priorities and evolving diagnostic technologies. The market was valued at USD 14.37 billion in 2025 and is projected to decline to USD 13.97 billion in 2026, further reaching USD 11.13 billion by 2034, reflecting a CAGR of -2.80% during the forecast period. Despite the decline, North America dominated the market with a 36.30% share in 2025, driven by strong healthcare infrastructure and continuous product innovations.
Point-of-care diagnostics enable rapid disease detection near the patient, eliminating the need for centralized laboratory testing. These tests provide results within 15-30 minutes, improving treatment decisions and patient outcomes. Technological advancements such as multiplex point-of-care testing (MPOCT), microfluidics, and nanotechnology have enhanced accuracy, speed, and usability, making these solutions vital in modern healthcare systems.
Market Dynamics
Growth Drivers
The increasing global prevalence of infectious diseases such as HIV, hepatitis, influenza, and tuberculosis remains a major driver for POC diagnostics. According to global health data, millions of people are affected annually, creating sustained demand for rapid and accessible diagnostic solutions.
Another important driver is the shift toward decentralized healthcare systems. Point-of-care testing allows diagnosis in clinics, homes, and remote settings, reducing dependency on centralized laboratories. This trend gained momentum during the COVID-19 pandemic and continues to influence healthcare delivery models.
Additionally, technological advancements in diagnostic platforms, including molecular diagnostics and nanotechnology-based testing, are improving sensitivity and reducing turnaround time. These innovations are expanding the application scope of POC diagnostics across multiple diseases.
Market Restraints
Despite these drivers, the market is experiencing a decline due to reduced demand post-COVID-19 pandemic, as emergency testing requirements have subsided. Furthermore, accuracy concerns and lack of skilled professionals in developing regions limit adoption. Errors caused by improper handling and insufficient training continue to challenge market growth.
Market Trends
A key trend shaping the market is the integration of nanotechnology in diagnostic devices. Nanoparticle-based tests offer high sensitivity and rapid detection, often requiring minimal sample volumes. These innovations are attracting significant research investments and improving diagnostic capabilities.
Another trend is the development of multiplex diagnostic platforms, which allow simultaneous detection of multiple pathogens in a single test. This enhances efficiency and reduces testing time, especially in critical care settings.
The market is also witnessing increased adoption of home-based and self-testing kits, reflecting a shift toward patient-centric healthcare and convenience-driven diagnostics.
Segmentation Analysis
By technique, the market includes lateral flow immunoassay, molecular diagnostics, agglutination tests, and flow-through assays. The lateral flow immunoassay segment dominates due to its simplicity, rapid results, and widespread availability. It is expected to hold a 31.2% share in 2026.
By disease, the market covers HIV, influenza, tuberculosis, hepatitis, MRSA, and others. Among these, clostridium difficile infections (CDI) hold a significant share due to high prevalence and increased testing demand in hospitals.
By end-user, the market is segmented into hospital bedside, physician offices, urgent care clinics, home testing, and nursing homes. The hospital bedside segment leads, driven by the growing number of hospitalized patients and the need for immediate diagnostic results. Meanwhile, home testing and urgent care clinics are gaining traction due to convenience and accessibility.
Regional Insights
North America leads the market with a value of USD 5.22 billion in 2025 and USD 5.07 billion in 2026, supported by advanced healthcare systems, strong regulatory approvals, and strategic collaborations among key players.
Europe holds the second-largest share, driven by mergers, acquisitions, and product portfolio expansion by major companies. Asia Pacific is expected to witness the highest growth potential, supported by increasing healthcare investments, rising disease burden, and expanding access to diagnostic technologies in countries such as China and India.
Latin America and the Middle East & Africa show slower growth due to limited awareness and lower healthcare spending, though gradual improvements in infrastructure are expected to support future demand.
Competitive Landscape
The market is semi-consolidated, with leading players such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, Cepheid Inc., Thermo Fisher Scientific, and BD. These companies focus on product innovation, strategic partnerships, and acquisitions to strengthen their market presence.
Recent developments include the launch of rapid diagnostic kits, multiplex assays, and portable testing devices, highlighting continuous innovation in the sector.
Conclusion
The infectious disease point-of-care diagnostics market is projected to decline from USD 14.37 billion in 2025 to USD 11.13 billion by 2034, primarily due to reduced post-pandemic demand and operational challenges. However, ongoing advancements in diagnostic technologies, increasing disease prevalence, and the shift toward decentralized healthcare will continue to support long-term relevance and innovation in the market.
Segmentation By Technique
- Lateral Flow Immunoassay (LFIA)
- Agglutination Test
- Flow-through test/Immunoconcentration Assay
- Molecular Diagnostics
- Others
By Disease
- HIV
- Hepatitis B Virus
- Pneumonia/Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV)
- Influenza
- Clostridium Difficile Infections (CDI)
- Hepatitis C Virus
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Tuberculosis (TB)
- COVID-19
- Others
By End-User
- Hospital Bedside
- Physician's Office Lab
- Urgent Care & Retail Clinics
- Home & Self-testing
- Nursing Home
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Infectious Diseases, By Key Countries, 2025
- 4.2. New Product Launches
- 4.3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
- 4.5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
- 4.6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
- 4.7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
- 4.8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Technique
- 5.1.1. Lateral Flow Immunoassay (LFIA)
- 5.1.2. Agglutination Tests
- 5.1.3. Flow-through Tests / Immunoconcentration Assays
- 5.1.4. Molecular Diagnostics
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease
- 5.2.1. Human Immunodeficiency Virus (HIV)
- 5.2.2. Hepatitis B Virus (HBV)
- 5.2.3. Pneumonia / Streptococcus Associated Infections
- 5.2.4. Respiratory Syncytial Virus (RSV)
- 5.2.5. Influenza
- 5.2.6. Clostridium difficile infection (CDI)
- 5.2.7. Hepatitis C Virus (HCV)
- 5.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 5.2.9. Tuberculosis (TB)
- 5.2.10. COVID-19
- 5.2.11. Others
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospital Bedside
- 5.3.2. Physician's Office Lab
- 5.3.3. Urgent Care & Retail Clinics
- 5.3.4. Home & Self-Testing
- 5.3.5. Nursing Homes
- 5.3.6. Others
- 5.4. Market Analysis, Insights and Forecast - By Geography
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Technique
- 6.1.1. Lateral Flow Immunoassay (LFIA)
- 6.1.2. Agglutination Tests
- 6.1.3. Flow-through Tests / Immunoconcentration Assays
- 6.1.4. Molecular Diagnostics
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease
- 6.2.1. Human Immunodeficiency Virus (HIV)
- 6.2.2. Hepatitis B Virus (HBV)
- 6.2.3. Pneumonia / Streptococcus Associated Infections
- 6.2.4. Respiratory Syncytial Virus (RSV)
- 6.2.5. Influenza
- 6.2.6. Clostridium difficile infection (CDI)
- 6.2.7. Hepatitis C Virus (HCV)
- 6.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 6.2.9. Tuberculosis (TB)
- 6.2.10. COVID-19
- 6.2.11. Others
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospital Bedside
- 6.3.2. Physician's Office Lab
- 6.3.3. Urgent Care & Retail Clinics
- 6.3.4. Home & Self-Testing
- 6.3.5. Nursing Homes
- 6.3.6. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Technique
- 7.1.1. Lateral Flow Immunoassay (LFIA)
- 7.1.2. Agglutination Tests
- 7.1.3. Flow-through Tests / Immunoconcentration Assays
- 7.1.4. Molecular Diagnostics
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease
- 7.2.1. Human Immunodeficiency Virus (HIV)
- 7.2.2. Hepatitis B Virus (HBV)
- 7.2.3. Pneumonia / Streptococcus Associated Infections
- 7.2.4. Respiratory Syncytial Virus (RSV)
- 7.2.5. Influenza
- 7.2.6. Clostridium difficile infection (CDI)
- 7.2.7. Hepatitis C Virus (HCV)
- 7.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 7.2.9. Tuberculosis (TB)
- 7.2.10. COVID-19
- 7.2.11. Others
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospital Bedside
- 7.3.2. Physician's Office Lab
- 7.3.3. Urgent Care & Retail Clinics
- 7.3.4. Home & Self-Testing
- 7.3.5. Nursing Homes
- 7.3.6. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Technique
- 8.1.1. Lateral Flow Immunoassay (LFIA)
- 8.1.2. Agglutination Tests
- 8.1.3. Flow-through Tests / Immunoconcentration Assays
- 8.1.4. Molecular Diagnostics
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease
- 8.2.1. Human Immunodeficiency Virus (HIV)
- 8.2.2. Hepatitis B Virus (HBV)
- 8.2.3. Pneumonia / Streptococcus Associated Infections
- 8.2.4. Respiratory Syncytial Virus (RSV)
- 8.2.5. Influenza
- 8.2.6. Clostridium difficile infection (CDI)
- 8.2.7. Hepatitis C Virus (HCV)
- 8.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 8.2.9. Tuberculosis (TB)
- 8.2.10. COVID-19
- 8.2.11. Others
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospital Bedside
- 8.3.2. Physician's Office Lab
- 8.3.3. Urgent Care & Retail Clinics
- 8.3.4. Home & Self-Testing
- 8.3.5. Nursing Homes
- 8.3.6. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Technique
- 9.1.1. Lateral Flow Immunoassay (LFIA)
- 9.1.2. Agglutination Tests
- 9.1.3. Flow-through Tests / Immunoconcentration Assays
- 9.1.4. Molecular Diagnostics
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease
- 9.2.1. Human Immunodeficiency Virus (HIV)
- 9.2.2. Hepatitis B Virus (HBV)
- 9.2.3. Pneumonia / Streptococcus Associated Infections
- 9.2.4. Respiratory Syncytial Virus (RSV)
- 9.2.5. Influenza
- 9.2.6. Clostridium difficile infection (CDI)
- 9.2.7. Hepatitis C Virus (HCV)
- 9.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 9.2.9. Tuberculosis (TB)
- 9.2.10. COVID-19
- 9.2.11. Others
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospital Bedside
- 9.3.2. Physician's Office Lab
- 9.3.3. Urgent Care & Retail Clinics
- 9.3.4. Home & Self-Testing
- 9.3.5. Nursing Homes
- 9.3.6. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Technique
- 10.1.1. Lateral Flow Immunoassay (LFIA)
- 10.1.2. Agglutination Tests
- 10.1.3. Flow-through Tests / Immunoconcentration Assays
- 10.1.4. Molecular Diagnostics
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease
- 10.2.1. Human Immunodeficiency Virus (HIV)
- 10.2.2. Hepatitis B Virus (HBV)
- 10.2.3. Pneumonia / Streptococcus Associated Infections
- 10.2.4. Respiratory Syncytial Virus (RSV)
- 10.2.5. Influenza
- 10.2.6. Clostridium difficile infection (CDI)
- 10.2.7. Hepatitis C Virus (HCV)
- 10.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 10.2.9. Tuberculosis (TB)
- 10.2.10. COVID-19
- 10.2.11. Others
- 10.3. Market Analysis, Insights and Forecast - By End User
- 10.3.1. Hospital Bedside
- 10.3.2. Physician's Office Lab
- 10.3.3. Urgent Care & Retail Clinics
- 10.3.4. Home & Self-Testing
- 10.3.5. Nursing Homes
- 10.3.6. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Thermo Fisher Scientific Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Quest Diagnostics Incorporated
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. BD
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. bioMerieux SA
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Cardinal Health, Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Cepheid
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Mesa Biotech
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Trinity Biotech
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Quidel Corporation
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Bio-Rad Laboratories, Inc.
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.12. Abbott
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Strategies
- 11.2.12.6. Financials (Based on Availability)
- 11.2.13. Other Prominent Players
- 11.2.1. F. Hoffmann-La Roche Ltd
List of Tables
- Table 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
- Table 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 05: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 06: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
- Table 07: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 08: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 09: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 10: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
8able 11: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 12: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 13: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 14: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
- Table 15: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 16: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 17: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 18: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
- Table 19: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 20: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 21: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
- Table 22: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
- Table 23: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 24: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
List of Figures
- Figure 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), by Region, 2025 & 2034
- Figure 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025 & 2034
- Figure 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Lateral Flow Immunoassay (LFIA), 2021-2034
- Figure 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Agglutination Tests, 2021-2034
- Figure 05: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Flow-through Tests / Immunoconcentration Assays, 2021-2034
- Figure 06: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Molecular Diagnostics, 2021-2034
- Figure 07 Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others, 2021-2034
- Figure 08: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025 & 2034
- Figure 09: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Human Immunodeficiency Virus (HIV) 2021-2034
- Figure 10: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis B Virus (HBV) 2021-2034
- Figure 11: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Pneumonia / Streptococcus Associated Infections 2021-2034
- Figure 12: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Respiratory Syncytial Virus (RSV) 2021-2034
- Figure 13: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Influenza 2021-2034
- Figure 14: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Clostridium difficile infection (CDI) 2021-2034
- Figure 15: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis C Virus (HCV) 2021-2034
- Figure 16: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Methicillin-Resistant Staphylococcus Aureus (MRSA) 2021-2034
- Figure 17: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Tuberculosis (TB) 2021-2034
- Figure 18: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By COVID-19 2021-2034
- Figure 19: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034
- Figure 20: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025 & 2034
- Figure 21: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hospital Bedside, 2021-2034
- Figure 22: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Physician's Office Lab2021-2034
- Figure 23: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Urgent Care & Retail Clinics 2021-2034
- Figure 24: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Home & Self Testing 2021-2034
- Figure 25: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Nursing Homes, 2021-2034
- Figure 26: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034
- Figure 27: Global Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Region, 2025 & 2034
- Figure 28: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
- Figure 29: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
- Figure 30: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
- Figure 31: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
- Figure 32: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
- Figure 33: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
- Figure 34: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country, 2025 & 2034
- Figure 35: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country, 2025
- Figure 36: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
- Figure 37: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
- Figure 38: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
- Figure 39: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
- Figure 40: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
- Figure 41: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
- Figure 42: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
- Figure 43: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
- Figure 44: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
- Figure 45: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
- Figure 46: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
- Figure 47: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
- Figure 48: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
- Figure 49: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
- Figure 50: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
- Figure 51: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
- Figure 52: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
- Figure 53: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
- Figure 54: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
- Figure 55: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
- Figure 56: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
- Figure 57: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
- Figure 58: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
- Figure 59: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
- Figure 60: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
- Figure 61: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
- Figure 62: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
- Figure 63: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
- Figure 64: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
- Figure 65: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
- Figure 66: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
- Figure 68: Global Infectious Disease Point-of-care (POC) Diagnostics Market Share, By Company, 2025
